

# Flowcytometric Analysis of Tumor Associated Macrophages in Invasive Ductal Carcinoma of Breast

Dawar Amani<sup>1\*</sup>, Zohair Mohammad Hassan<sup>2</sup>, Fatemeh Ravangard<sup>1</sup>, Susan Frazmand<sup>2</sup>, Mojtaba Karim Zadeh<sup>2</sup>

<sup>1</sup>Department of Immunology, Medical School, Ardabil University of Medical Sciences, Ardabi, Iran, <sup>2</sup>Department of Immunology, Medical School, Tarbiat Modarres University, Tehran, Iran.

## ABSTRACT

**Background:** Invasive ductal carcinoma is the most common type of breast cancer in Iran. Impaired immune responses occur frequently in cancer patients, but the mechanisms of the induced immune defects remain poorly understood. It is believed that infiltrated immune cells, especially macrophages, may provide help for tumor cell growth and metastasis. **Objective:** To analyze the status of tumor associated macrophages (TAM) by immunophenotyping method. **Methods:** Twenty-three women suffering from breast cancer were examined; nineteen of them were confirmed histologically to have invasive ductal carcinoma. Tumor cell suspensions from biopsy specimens and peripheral blood mononuclear cells from patients and matched controls were processed for analysis by flow cytometry. **Results:** No significant changes in the percentages of intra-tumor leukocytes and macrophages in the different stages of tumor were observed. There were no significant differences in the percentages of leukocytes (CD45<sup>+</sup>), monocytes (CD45<sup>+</sup>/CD14<sup>+</sup>) and activated monocytes (CD14<sup>+</sup>/HLA-DR<sup>+</sup> and CD14<sup>+</sup>/CD16<sup>+</sup>) in the peripheral blood of patients and controls. **Conclusion:** The results of this study indicated that human breast cancer contain substantial, although variable numbers of macrophages, however, the activation status of these macrophages remain to be elucidated.

**Keywords:** Breast Cancer, Tumor Associated Macrophages, Tumor Immunity

\*Corresponding author: Dr. Dawar Amani, Department of Immunology, Medical School, Ardabil University of Medical Sciences, Ardabi, Iran. Tel: (+) 98 912 508 4787; Fax: (+) 98 451 551 0057, e-mail: amanid@sums.ac.ir

## INTRODUCTION

Invasive ductal carcinoma is the most common type of breast cancer in Iran. Impaired immune responses occur frequently in cancer patients, but the mechanisms of the induced immune defects remain poorly understood (1). In many carcinomas, infiltrating macrophages are commonly found closely associated with tumor but little is known concerning the nature or significance of adherent molecules in these cellular interactions (2). In addition, the presence of immature dendritic cells within the tumor has been reported, whereas mature dendritic cells are located in peri-tumoral area (3).

In many solid tumors the abundance of tumor-associated macrophages (TAMs) is correlated with poor prognosis (4). Current evidence suggests that in established, progressively growing solid tumors, TAMs are reprogrammed to induce immune suppression of host defenses in situ, through release of specific cytokines, prostanoids and other humoral mediators. This disordered response, results in the inhibition of effective anti-cancer cell-mediated immune mechanisms. Concurrently, TAMs produce tumor growth promoting factors (5). Other studies have shown that macrophage expression urokinase (uPA) plays a key role in the degradation of tumor matrix and promotes tumor progression (6).

The summation of this complex interplay of biological factors results in progressive tumor growth and tumor cell dissemination. A better understanding of these complex inter-relationships should form the basis of novel strategies to eradicate tumor cells in man and animals. Previous studies suggested the production of cytokines as a significant parameter in the regulation of tumor prognosis and indicated a defect in IL-12 production capability while generating higher amounts of IL-10 (7).

In this study we aimed to measure the percentage of macrophages infiltrated in tumor by flowcytometer, and estimate the activity of these cells in different stages of breast tumors.

## MATERIAL AND METHODS

**Patients.** Twenty-three patients with breast cancer who underwent surgical procedure were studied in Cancer Institute of Imam-Khomeini hospital, Tehran. Patients with a history of chemotherapy and/or radiotherapy were excluded from study. The age of patients ranged from 26-70 yr (mean 45.4). Nineteen of the patients were diagnosed pathologically to have invasive ductal carcinoma (82.6%), two of the patients had invasive lobular carcinoma (8.7%), one patient had ductal carcinoma in situ, one patient had atypical modularly carcinoma and one patient had fibrocystic breast disease. Peripheral blood of nine cancer patients and 9 matched control women were collected in EDTA-coated tubes. The mononuclear cell fraction of blood samples were isolated by ficole and processed for immunostaining (see below). The patients and controls participated in this study after informed consent.

**Preparation of Tumor Cell Suspension.** Biopsies of human solid tumor were cut into small pieces with forceps and scalpel. The pieces were rinsed twice with phosphate buffer saline, then 5 ml of cocktail enzymes (0.05 mg/ml collagenase and 0.002 mg/ml DNase) were added and the mixture was placed in 37°C for 2-4 hrs. The suspension was passed through 150-micron stainless steel mesh. Cells were washed twice and labeled with monoclonal antibodies.

**Immunophenotyping.** The following fluorescent monoclonal antibodies (mAb) were used to identify leukocytes and TAM in both PBL and tumor cell suspensions: anti-CD45 for detection of leukocytes' anti-CD45/CD14 for detection of monocyte/macrophages and both anti-CD14/CD16 and anti-CD14/HLA-DR for detection of activated monocyte/macrophages (8). We established the reference immunophenotypic pattern using stan-

standard procedures. In this study 100µl of each blood sample was treated as follows; each sample was immunostained with 10µl of each mAbs directly conjugated with Fluorescein Isothiocyanate (FITC) or R-Phycoerythrin (RPE). Each sample was then fixed with paraformaldehyed and kept in 2-8 °C and dark for about 24 hrs (8).

**Flowcytometric Analysis.** Cell sample were measured on a coulter flowcytometer with serial filter configuration. The analysis was focused on the myeloid areas of the forward and side scatters. Double stained cells were analyzed using coulter software.

**Statistical Analysis.** One-way analysis of variation (ANOVA) and Kruskal-Wallis nonparametric test were employed using SPSS software.

## RESULTS

### Comparison of PBL monocytes between breast cancer patients and controls

Table 1 summarized the percentages of PBL leukocytes and monocytes in both patients and control group. Flowcytometric analysis was done in the gate of monocyte. Results indicated no significant differences in the percentage of leukocytes and monocytes compared to the control group.

The percentage of CD16<sup>+</sup> cells showed significant differences between two groups (P = 0.007) and the number of these cells showed a significant decrease in breast cancer patients.

**Table1. Flowcytometric analysis of leukocytes and monocytes in peripheral blood of breast cancer patients and control group**

CD Marker	Breast Cancer (n = 9)	Control (n = 9)	P value
CD45 <sup>+</sup> <sup>a</sup>	88.5	92.5	0.2
CD45 <sup>+</sup> /CD14 <sup>+</sup>	2	3.1	0.44
$\frac{CD45^+/CD14^+}{CD45^+} \times 100$	2.7	3.4	0.44
CD16 <sup>+</sup>	19.7	54.2	0.007
CD14 <sup>+</sup> /CD16 <sup>+</sup>	0.4	0.9	0.1
$\frac{CD14^+/CD16^+}{CD45^+} \times 100$	0.4	1	0.1
HLA-DR <sup>+</sup>	8.4	6.6	0.3
D14 <sup>+</sup> /HLA-DR <sup>+</sup>	0.6	0.7	0.44
$\frac{D14^+/HLA-DR^+}{CD45^+} \times 100$	0.6	0.8	0.44

<sup>a</sup> values are shown in mean percentages and analysis was done in monocyte gate

**Percentage of Tumor Associated Macrophages.** In order to evaluate the percent of intratumor TAM, 23 patients were divided into two groups (IDC group and ILC+DCI+AMC group). The normal or benign tissues were considered as group 3. All the data was analyzed in the leukocyte gate. As shown in Table 2 the mean percentage of intratumor CD14<sup>+</sup>/HLA-DR<sup>+</sup> cells were significantly (P = 0.03) higher in control group compared with breast cancer groups (group 1 and 2).

**Correlation between TAM and Clinical Staging of Tumor.** In order to assess the correlation between the percentage and activity of peripheral blood monocytes and TAM in different stages of tumor, patients having stages 1, 2 and 3 of the disease were evaluated. Results in table 3 indicated no significant differences between different stages of tumor. The CD45<sup>+</sup>, CD 14<sup>+</sup>/CD16<sup>+</sup> and CD14<sup>+</sup>/HLA-DR<sup>+</sup> cells decreased remarkably in stage II of breast cancer

and in the cases of CD45<sup>+</sup> and CD14<sup>+</sup>/HLA-DR<sup>+</sup> cells, this decrease was considerable but statistically insignificant (Table3).

**Table 2. Immunostatus of tumor associated macrophages in breast cancer patients**

Marker	Group 1 (n =19) IDC*	Group 2 (n = 4) ILC+DCI+AMC*	Group 3 (n = 3) Benign/control	P value
CD45 <sup>+</sup>	16.4	19.53	12.85	0.9
CD45 <sup>+</sup> /CD14 <sup>+</sup>	2.64	1.86	3.72	0.4
$\frac{CD45^+/CD14^+}{CD45^+} \times 100$	24.49	30.37	33.77	0.8
CD16 <sup>+</sup>	17.18	6.6	11.7	0.5
CD14 <sup>+</sup> /CD16 <sup>+</sup>	1.56	1.38	1.6	0.96
$\frac{CD14^+/CD16^+}{CD45^+} \times 100$	12.3	27.18	11.07	0.3
HLA-DR <sup>+</sup>	14.71	11.18	19.5	0.4
CD14 <sup>+</sup> /HLA-DR <sup>+</sup>	1.57	1.23	3.03	0.03
$\frac{D14^+/HLA-DR^+}{CD45^+} \times 100$	13.62	14.42	16.65	0.35

\*IDC = Invasive ductal carcinoma; ILC = Invasive lobular carcinoma; DCI = Ductal carcinoma in situ; AMC = Atypical modularly carcinoma

In another analysis, the sizes of tumors correlated with the status of leukocytes and TAM. Results in Table 4 indicated no significant decrease in the total leukocyte and TAM count when the tumor size increased.

**Table 3. Immunostatus of monocyte/macrophages in different stages of Invasive ductal carcinoma patients<sup>a</sup>**

CD Marker	PBL cells				Intratumor cells			
	stages: I	II	III	P Value	stages: I	II	III	P Value
CD45 <sup>+</sup>	88.25	94.57	82.57	0.2	14	9.18	28.9	0.07
CD45 <sup>+</sup> /CD14 <sup>+</sup>	1.97	2.24	1.85	0.9	2.78	1.95	3.57	0.25
CD14 <sup>+</sup> /CD16 <sup>+</sup>	0.3	0.25	0.4	0.6	2.77	0.65	2.05	0.06
CD14 <sup>+</sup> /HLA-DR <sup>+</sup>	0.63	0.43	0.63	0.8	2.33	1.23	1.5	0.35

<sup>a</sup> The minimum number of cases used in each stage of tumor was three

**Table 4. Immunostatus of monocyte/macrophages in Invasive ductal carcinoma tumors with different sizes<sup>a</sup>**

CD Marker	Intratumor			Cells	P Value
	<2cm	2-3cm	>3cm		
CD45 <sup>+</sup>	19.6	9.8	19	0.6	
CD45 <sup>+</sup> /CD14 <sup>+</sup>	2.8	2.8	2.3	0.9	
CD14 <sup>+</sup> /CD16 <sup>+</sup>	2.2	1.2	0.9	0.3	
CD14 <sup>+</sup> /HLA-DR <sup>+</sup>	1.5	0.9	1.9	0.5	

cm= centimeter

<sup>a</sup>The minimum number of cases used in each stage of tumor was three

## DISCUSSION

The immune system is capable of responding to cancer as evidenced by systemic, regional, and intratumoral leukocyte activation. For individual patients there is no predictable relationship between leukocyte composition, or function, and the prognosis of the disease (9).

Immunohistological analysis of tissue sections and isolation of cells by mechanical desegregation and enzymatic digestion of excised tumors are the established methods used to study the cell composition of tumors (10). Previous published studies indicated that the number of macrophages is substantial but varies greatly among the different studied tumors (11,12). Macrophages also infiltrate metastatic lesions, although TAMs have been less extensively studied in secondary tumor deposits (13).

The Results of our study indicated that CD16<sup>+</sup> bearing cells significantly decrease in the PBL of breast cancer patients (Table 1). In the PBL population of human activated monocytes and natural killer (NK) cells express CD16 marker, therefore it is reasonable to assume a significant decrease of these two important cell populations in our patients.

We also evaluated the presence of macrophages within the invasive ductal carcinoma and other tumors of breast compared to fibrocystic benign tumor. The range of infiltrated CD45<sup>+</sup> cells was variable (2.7 and up to 61.7). The range of infiltrated CD14<sup>+</sup> cells was 0.7 and up to 4.5 which is consistent with previous results of van Rarenswaay Claasan et al. (11) and Toomey et al. (14).

This wide range of variation in cell infiltration is attributed to different stages of tumors and the rate of tumor growth. The activity of macrophages was studied by using CD16<sup>+</sup> and HLA-DR<sup>+</sup> markers. In stage II of breast cancer the CD16 and HLA-DR bearing macrophages decreased remarkably (Table 3) and this may confirm suppression of tumor infiltrating immune cells (5).

Solid tumors, both primary lesions and metastases, become infiltrated by large numbers of tumor-associated leukocytes. These are heterogeneous populations of cells consisting of various (and variable) subsets of T cells (helper, suppressor and cytotoxic), B cells, natural killer (NK) cells, and macrophages (11). However, the biological relevance and clinical significance of these different cellular infiltrates remains the subject of conflicting reports and continuing debate. In view of their normally defensive and beneficial role *in vivo*, leukocytes infiltrating tumor were originally believed to herald an immune response to the growing neoplasm. One of the first direct indications that killing of tumor cells by macrophages involved direct contact between them and tumor cells was provided by Bucana et al. (15). They produced morphological evidence on translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of target cells. Electron microscopic observations have shown that destruction of tumor cells by activated macrophages is a non-phagocytic, lytic process (15). It is reported that the interaction between activated macrophages and the neoplastic cells involves intimate cellular binding, is temperature dependent and requires viable, metabolically active effector cells (16). Recently co-cultivation of tumor cells with macrophages has been shown to enhance invasiveness of malignant cells in a TNF-alpha dependent manner (17). However, the spontaneous regression of an established tumor is a rare event, suggesting that in progressively growing tumors, the immunocompetence and anti-cancer effects of these cells within the tumor cell milieu may be compromised. Moreover, subpopulations of associated-associated leukocytes have been shown to be detrimental to the host and beneficial to progressive tumor growth (12,14).

It is possible that stimulation of the activity of macrophages can help us in increasing the binding of activated macrophages to tumor cells and selectively increase cytolysis of the tumor cells.

## REFERENCES

1. Remedi MM, Hliba E, Demarchi M, Depiante-Depaoli M. Relationship between immune state and tumor growth rate in rats bearing progressive and non-progressive mammary tumors. *Cancer Immunol Immunother.* 1998;46:350-4.
2. Nath D, Hartnell A, Happerfield L, Miles DW, Burchell J, Taylor-Papadimitriou J et al. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. *Immunology.* 1999;98:213-9.
3. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. *J Exp Med.* 1999;190:1417-26.
4. Lin EY, Pollard JW. Macrophages: modulators of breast cancer progression. *Novartis Found Symp.* 2004;256:158-68.
5. al-Sarireh B, Eremin O. Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth. *J R Coll Surg Edinb.* 2000;45:1-16.
6. Hildenbrand R, Jansen C, Wolf G, Bohme B, Berger S, von Minckwitz G et al. Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. *Lab Invest.* 1998;78:59-71.
7. Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S et al. Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. *Immunol Lett.* 1999;68:355-8.
8. Lal RB, Edison LJ, Chused TM. Fixation and long-term storage of human lymphocytes for surface marker analysis by flow cytometry. *Cytometry.* 1988;9:213-9.
9. Wong PY, Staren ED, Tereshkova N, Braun DP. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. *J Surg Res.* 1998;76:95-103.
10. O'Sullivan C, Lewis CE. Tumour-associated leucocytes: friends or foes in breast carcinoma. *J Pathol.* 1994;172:229-35.
11. van Ravenswaay Claasen HH, Kluin PM, Fleuren GJ. Tumor infiltrating cells in human cancer. On the possible role of CD16+ macrophages in antitumor cytotoxicity. *Lab Invest.* 1992;67:166-74.
12. Toomey D, Harmey J, Condron C, Kay E, Bouchier-Hayes D. Phenotyping of immune cell infiltrates in breast and colo-rectal tumours. *Immunol Invest.* 1999;28:29-41.
13. Brunda MJ, Sulich V, Wright RB, Palleroni AV. Tumoricidal activity and cytokine secretion by tumor-infiltrating macrophages. *Int J Cancer.* 1991;48:704-8.
14. O'Sullivan C, Lewis CE, Harris AL, McGee JO. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. *Lancet.* 1993;342:148-9.
15. Bucana C, Hoyer LC, Hobbs B, Breesman S, McDaniel M, Hanna MG Jr. Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells. *Cancer Res.* 1976;36:4444-58.
16. Marino PA, Adams DO. Interaction of Bacillus Calmette--Guerin-activated macrophages and neoplastic cells in vitro. I. Conditions of binding and its selectivity. *Cell Immunol.* 1980;54:11-25.
17. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. *Carcinogenesis.* 2004;25:1543-9.